Research programme: peptide YY3-36 - Wyeth

Drug Profile

Research programme: peptide YY3-36 - Wyeth

Alternative Names: PYY3-36 - Wyeth

Latest Information Update: 13 Aug 2009

Price : $50

At a glance

  • Originator Imperial Innovations; Oregon Health & Science University
  • Developer Wyeth
  • Class Antihyperglycaemics; Obesity therapies; Peptides
  • Mechanism of Action Neuropeptide Y2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Obesity

Most Recent Events

  • 13 Aug 2009 No development reported - Preclinical for Obesity in United Kingdom (Parenteral)
  • 18 Dec 2008 Thiakis has been acquired and merged into Wyeth
  • 18 Aug 2005 Preclinical trials in Obesity in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top